The agreement includes distribution in the USA, Canada, European Union, and other significant markets such as India and Japan.
Sabinsa Corp. (East Windsor, NJ) and Postbiotics Inc. (Winston-Salem, NC) announced a multinational distribution agreement for the postbiotic ingredient, PoZibio, which supports age-related digestive health conditions such as Leaky Gut Syndrome. The agreement includes distribution in the USA, Canada, European Union, and other significant markets such as India and Japan.
According to a press release, PoZibio is a patent-pending postbiotic composition of Lipoteichoic Acid, isolated from the cell walls of a heat-treated strain of Lactobacillus paracasei(Patent Number US 11,622,981 B2). The composition was reportedly discovered by researchers at Wake Forest University College of Medicine, and because of its low dose, heat stability, and neutral flavor profile, PoZibio is suitable for a range of applications such as dietary supplements, medical foods, and dietary supplements.
“The gut-brain axis benefits we have shown from PoZibio are compelling,” said Hariom Yadav, PhD, associate professor of neurosurgery and brain repair and director of the University of Florida’s Center of Microbiome Research, in a press release. Yadav discovered the ingredient during his time at Wake Forest University. “PoZibio has been shown to increase the mucous layer of the gut wall, inhibit age-related inflammation (inflammaging), support cognitive function, and promote muscle and metabolic health, in prior and ongoing research,” he explained.
“I’m pleased to bring forth an ingredient for a condition that is very under addressed in the marketplace,” said Shaheen Majeed, global CEO and managing director of Sabinsa, in a press release. “Additionally, this marks one of the very first partnerships Sabinsa enters into globally, and at its core represents the best of science and functionality.”
“We are pleased to be working with Sabinsa, and believe their global sales organization and manufacturing prowess are perfect complements to our world-class research,” added Doug Lynch, co-founding partner and chief commercial officer of Postbiotics Inc. “This distribution partnership with Sabinsa for will ensure consumer brands of supplements and foods in the United States and beyond will experience the many benefits from postbiotics on improving health and lifespan.”
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.